|
2.5 Etiologie - Gènes
|
|
|
Is bad luck the leading cause of cancer? [NHS Choices]
|
|
|
|
|
|
The
possibility that random gene mutations can occur when the body's cells
repeatedly divide is obviously highly plausible and not really that
revolutionary a theory. However, these researchers have tried to
quantify exactly what proportion of cancers could be down to chance.
This brings us to the greatest limitation of this research: these are
only estimates.
|
|
|
|
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
Nicotine e-cigarettes legalised – Expert Reaction [Science Media Centre]
|
|
|
|
|
|
Associate
Health Minister Nicky Wagner has announced the sale of nicotine
e-cigarettes and e-liquid will be legalised. Controls will include
restricting sales to over 18-year-olds and prohibiting vaping in indoor
workplaces and other areas where smoking is banned under the Smoke-free
Environments Act.
|
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
5. Traitements
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
BMS seeks leg up in immuno-oncology with Parker Institute and CRI pact [FierceBiotech]
|
|
|
|
|
|
The
deal gives BMS a channel into a virtual network of more than 300 cancer
specialists and 60 labs set up by ex-Facebook and Napster billionaire
Sean Parker last year with a $250 million warchest. Add in the extensive
patient group and scientist connections of the non-profit CRI—which
teamed up with the Parker Institute last year—and the partners say they
have a potent toolbox for clinical research and cancer drug development.
|
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.4 Traitements - Economie
|
|
|
Patients call for halt to NICE changes [PharmaTimes]
|
|
|
|
|
|
Led
by Genetic Alliance UK, the coalition argues that proposals that limit
recommendations by NICE’s HST Evaluation programme will prevent access
to innovative treatments for rare genetic conditions in England, “and
send a chilling message to the life sciences sector that runs contrary
to messages from other parts of Government”.
|
|
|
|
|
|
|
|
Final NICE no for Shire’s pancreatic cancer drug [PharmaTimes]
|
|
|
|
|
|
The
National Institute for Health and Care Excellence has now published
final guidance rejecting the drug’s use, in combination for
5-fluorouracil (5-FU) and leucovorin (LV), for metastatic pancreatic
cancer that has progressed after gemcitabine-based therapy.
|
|
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
White House proposes new, sweeping budget cuts at NIH [STAT]
|
|
|
|
|
|
The
Trump administration is also proposing a $314 million cut at the
Centers for Disease Control and Prevention through reductions to
occupational safety and public health preparedness grants, as well as
domestic and global HIV/AIDS programs.
|
|
|
|
|
|
|
Donald Trump aims for $1.2B in NIH cuts this year [FierceBiotech]
|
|
|
|
|
|
Congress
will have the final say as to whether these cuts go through, but does
not have to follow the White House’s wishes. Trump wants to cut back on a
number of areas in order to boost spending on the military, and store
up funds for a proposed border wall with Mexico.
|
|
|
|
|
|
|
6.11 Patients
|
|
|
New cancer treatments should inform patients about quality of life beyond side effects [STAT]
|
|
|
|
|
|
When
I first started my career as an oncology/hematology nurse practitioner
and educator more than 25 years ago, the main goal of cancer treatment
was usually to extend life, no matter what the quality of that extra
life was. Joey’s experience made me face a moral dilemma — was this the
right approach, or should we ensure that whatever extra time we are
giving to patients is actually worth living?
|
|
|
|
|
|
|
6.6 Publications
|
|
|
ORCID in Europe: Reasons to be Cheerful [ORCID]
|
|
|
|
|
|
We
welcomed five new national ORCID consortia members from Europe during
2016. Belgium, Finland, Germany, the Netherlands, and Sweden joined
Denmark, Italy, and the UK to bring the total number of consortia
members in Europe to eight, collectively representing 215 institutions.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|